LV232 / Vigonvita Life Sci - LARVOL DELTA

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules (clinicaltrials.gov) - P1 | N=49 | Completed | Sponsor: Vigonvita Life Sciences | Recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Dec 2024 | Trial primary completion date: Oct 2025 ➔ Dec 2024

Trial completion • Trial completion date • Trial primary completion date

A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Vigonvita Life Sciences | Trial primary completion date: May 2025 ➔ Jan 2025 | Recruiting ➔ Completed

Trial completion • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting | Trial completion date: Feb 2026 ➔ Dec 2026 | Trial primary completion date: Feb 2026 ➔ Sep 2026

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: May 2025 ➔ Oct 2025 | Trial primary completion date: May 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Vigonvita Life Sciences | N=48 ➔ 80 | Trial completion date: May 2025 ➔ Oct 2025 | Trial primary completion date: May 2025 ➔ Oct 2025

Enrollment change • Trial completion date • Trial primary completion date

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of Major Depressive Disorder (MDD) (clinicaltrials.gov) - P2 | N=500 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Dec 2024 ➔ May 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Trial completion date • Trial primary completion date

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Dec 2024 ➔ May 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Trial completion date • Trial primary completion date

A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: Vigonvita Life Sciences | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ May 2025 | Trial primary completion date: Dec 2024 ➔ May 2025

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET (clinicaltrials.gov) - P1 | N=8 | Active, not recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2024 ➔ Dec 2024

Enrollment closed • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Jul 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Jul 2024 ➔ Dec 2024 | Trial primary completion date: Jul 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date

A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P1 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting

Enrollment open

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Feb 2024 ➔ Jul 2024 | Trial primary completion date: Feb 2024 ➔ Jun 2024

Trial completion date • Trial primary completion date

Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P1 trial

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting

Enrollment open

Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P1 trial